Published in Arthritis Res Ther on July 23, 2009
A cytokine-centric view of the pathogenesis and treatment of autoimmune arthritis. J Interferon Cytokine Res (2011) 1.12
Th 17 cells interplay with Foxp3+ Tregs in regulation of inflammation and autoimmunity. Front Biosci (Landmark Ed) (2010) 1.11
IL-17A expression is localised to both mononuclear and polymorphonuclear synovial cell infiltrates. PLoS One (2011) 1.10
Targeting interleukin-17 in patients with active rheumatoid arthritis: rationale and clinical potential. Ther Adv Musculoskelet Dis (2013) 1.05
Rheumatoid arthritis pathophysiology: update on emerging cytokine and cytokine-associated cell targets. Rheumatology (Oxford) (2014) 0.98
IL-17A and Th17 cells in lung inflammation: an update on the role of Th17 cell differentiation and IL-17R signaling in host defense against infection. Clin Dev Immunol (2013) 0.97
Current perspectives on the role of IL-17 in autoimmune disease. J Inflamm Res (2010) 0.96
IL-17 in the rheumatologist's line of sight. Biomed Res Int (2013) 0.95
Plasma levels of IL-37 and correlation with TNF-α, IL-17A, and disease activity during DMARD treatment of rheumatoid arthritis. PLoS One (2014) 0.94
Cytokine networks in systemic lupus erythematosus. J Biomed Biotechnol (2010) 0.93
Basic biology and role of interleukin-17 in immunity and inflammation. Periodontol 2000 (2015) 0.92
Altered immunoregulation in rheumatoid arthritis: the role of regulatory T cells and proinflammatory th17 cells and therapeutic implications. Mediators Inflamm (2015) 0.92
Regulation and function of IL-17A- and IL-22-producing γδ T cells. Cell Mol Life Sci (2011) 0.91
Pathologic finding of increased expression of interleukin-17 in the synovial tissue of rheumatoid arthritis patients. Int J Clin Exp Pathol (2013) 0.91
Cytokines in immune-mediated inflammatory myopathies: cellular sources, multiple actions and therapeutic implications. Clin Exp Immunol (2014) 0.90
Interleukin (IL)-17A, F and AF in inflammation: a study in collagen-induced arthritis and rheumatoid arthritis. Clin Exp Immunol (2014) 0.89
Serum levels of IL-17, IL-4, and INFγ in Serbian patients with early rheumatoid arthritis. J Res Med Sci (2014) 0.87
Th17 cells favor inflammatory responses while inhibiting type I collagen deposition by dermal fibroblasts: differential effects in healthy and systemic sclerosis fibroblasts. Arthritis Res Ther (2013) 0.87
TNFα promotes Th17 cell differentiation through IL-6 and IL-1β produced by monocytes in rheumatoid arthritis. J Immunol Res (2014) 0.82
Dendritic cells provide a potential link between smoking and inflammation in rheumatoid arthritis. Arthritis Res Ther (2012) 0.81
Early biomarkers of joint damage in rheumatoid and psoriatic arthritis. Arthritis Res Ther (2015) 0.81
Blockade of recombinant human IL-6 by tocilizumab suppresses matrix metalloproteinase-9 production in the C28/I2 immortalized human chondrocyte cell line. Integr Mol Med (2015) 0.80
Emerging MRI methods in rheumatoid arthritis. Nat Rev Rheumatol (2010) 0.80
TLR2 elicits IL-17-mediated RANKL expression, IL-17, and OPG production in neutrophils from arthritic mice. Mediators Inflamm (2014) 0.80
Molecular Insight into Gut Microbiota and Rheumatoid Arthritis. Int J Mol Sci (2016) 0.78
Patients with the most advanced rheumatoid arthritis remain with Th1 systemic defects after TNF inhibitors treatment despite clinical improvement. Rheumatol Int (2013) 0.78
Salubrinal Suppresses IL-17-Induced Upregulation of MMP-13 and Extracellular Matrix Degradation Through the NF-kB Pathway in Human Nucleus Pulposus Cells. Inflammation (2016) 0.77
Increased IL-17A/IL-17F expression ratio represents the key mucosal T helper/regulatory cell-related gene signature paralleling disease activity in ulcerative colitis. J Gastroenterol (2016) 0.76
Tissue specific CD4+ T cell priming determines the requirement for interleukin-23 in experimental arthritis. Arthritis Res Ther (2014) 0.75
Ex vivo model exhibits protective effects of sesamin against destruction of cartilage induced with a combination of tumor necrosis factor-alpha and oncostatin M. BMC Complement Altern Med (2016) 0.75
Inhibition of G-Protein βγ Signaling Decreases Levels of Messenger RNAs Encoding Proinflammatory Cytokines in T Cell Receptor-Stimulated CD4(+) T Helper Cells. J Mol Signal (2015) 0.75
IL17A and IL17F gene polymorphisms in patients with rheumatoid arthritis. BMC Musculoskelet Disord (2016) 0.75
Gene Expression Profiling of IL-17A-Treated Synovial Fibroblasts from the Human Temporomandibular Joint. Mediators Inflamm (2015) 0.75
Expanded role for interleukin-17 in rheumatoid arthritis. Clin Rheumatol (2011) 0.75
Influence of Periostin on Synoviocytes in Knee Osteoarthritis. In Vivo (2017) 0.75
The Relationship of Cytokines IL-13 and IL-17 with Autoantibodies Profile in Early Rheumatoid Arthritis. J Immunol Res (2016) 0.75
Integrating longitudinal serum IL-17 and IL-23 follow-up, along with autoantibodies variation, contributes to predict bullous pemphigoid outcome. Sci Rep (2015) 0.75
The impact of disease activity and tumour necrosis factor-α inhibitor therapy on cytokine levels in juvenile idiopathic arthritis. Clin Exp Immunol (2016) 0.75
Regulatory Effect of Iguratimod on the Balance of Th Subsets and Inhibition of Inflammatory Cytokines in Patients with Rheumatoid Arthritis. Mediators Inflamm (2015) 0.75
Higher efficacy of anti-IL-6/IL-21 combination therapy compared to monotherapy in the induction phase of Th17-driven experimental arthritis. PLoS One (2017) 0.75
Gastrointestinal and Hepatic Disease in Rheumatoid Arthritis. Rheum Dis Clin North Am (2018) 0.75
Regulatory effects of zinc on cadmium-induced cytotoxicity in chronic inflammation. PLoS One (2017) 0.75
The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum (1988) 111.05
Interleukin-17 family members and inflammation. Immunity (2004) 16.16
T cell interleukin-17 induces stromal cells to produce proinflammatory and hematopoietic cytokines. J Exp Med (1996) 8.59
IL-17 in synovial fluids from patients with rheumatoid arthritis is a potent stimulator of osteoclastogenesis. J Clin Invest (1999) 7.66
Human interleukin-17: A T cell-derived proinflammatory cytokine produced by the rheumatoid synovium. Arthritis Rheum (1999) 6.39
Herpesvirus Saimiri encodes a new cytokine, IL-17, which binds to a novel cytokine receptor. Immunity (1995) 5.96
IL-17 stimulates the production and expression of proinflammatory cytokines, IL-beta and TNF-alpha, by human macrophages. J Immunol (1998) 5.79
Th17 functions as an osteoclastogenic helper T cell subset that links T cell activation and bone destruction. J Exp Med (2006) 5.63
Cytokines and cytokine inhibitors or antagonists in rheumatoid arthritis. Arthritis Rheum (1990) 4.39
How to read radiographs according to the Sharp/van der Heijde method. J Rheumatol (2000) 4.31
Regulation of matrix biology by matrix metalloproteinases. Curr Opin Cell Biol (2004) 4.16
Increased expression of interleukin 23 p19 and p40 in lesional skin of patients with psoriasis vulgaris. J Exp Med (2004) 4.02
Enhancing effect of IL-17 on IL-1-induced IL-6 and leukemia inhibitory factor production by rheumatoid arthritis synoviocytes and its regulation by Th2 cytokines. J Immunol (1998) 3.70
Amelioration of epidermal hyperplasia by TNF inhibition is associated with reduced Th17 responses. J Exp Med (2007) 3.68
IL-1-independent role of IL-17 in synovial inflammation and joint destruction during collagen-induced arthritis. J Immunol (2001) 3.32
Long-term course and outcome of functional capacity in rheumatoid arthritis: the effect of disease activity and radiologic damage over time. Arthritis Rheum (1999) 3.08
Biomarkers predict radiographic progression in early rheumatoid arthritis and perform well compared with traditional markers. Arthritis Rheum (2007) 2.50
In vitro and in situ expression of IL-23 by keratinocytes in healthy skin and psoriasis lesions: enhanced expression in psoriatic skin. J Immunol (2006) 2.44
Induction, function and regulation of IL-17-producing T cells. Eur J Immunol (2008) 2.38
Synovial membrane cytokine expression is predictive of joint damage progression in rheumatoid arthritis: a two-year prospective study (the DAMAGE study cohort). Arthritis Rheum (2006) 2.17
IL-17 derived from juxta-articular bone and synovium contributes to joint degradation in rheumatoid arthritis. Arthritis Res (2001) 2.12
Contribution of interleukin 17 to synovium matrix destruction in rheumatoid arthritis. Cytokine (2000) 2.11
Studies of the articular cartilage proteoglycan aggrecan in health and osteoarthritis. Evidence for molecular heterogeneity and extensive molecular changes in disease. J Clin Invest (1992) 2.10
Interleukin-17 receptor deficiency results in impaired synovial expression of interleukin-1 and matrix metalloproteinases 3, 9, and 13 and prevents cartilage destruction during chronic reactivated streptococcal cell wall-induced arthritis. Arthritis Rheum (2005) 1.93
IL-4 gene therapy for collagen arthritis suppresses synovial IL-17 and osteoprotegerin ligand and prevents bone erosion. J Clin Invest (2000) 1.74
Interleukin-17 stimulates C-reactive protein expression in hepatocytes and smooth muscle cells via p38 MAPK and ERK1/2-dependent NF-kappaB and C/EBPbeta activation. J Biol Chem (2007) 1.69
Interleukin-17 acts independently of TNF-alpha under arthritic conditions. J Immunol (2006) 1.59
The role of oncostatin M in animal and human connective tissue collagen turnover and its localization within the rheumatoid joint. Arthritis Rheum (1998) 1.53
Blockade of tumor necrosis factor in collagen-induced arthritis reveals a novel immunoregulatory pathway for Th1 and Th17 cells. J Exp Med (2008) 1.51
Serum matrix metalloproteinase 3 is an independent predictor of structural damage progression in patients with ankylosing spondylitis. Arthritis Rheum (2007) 1.49
Chemokines and chemokine receptors in rheumatoid arthritis. Semin Immunol (2003) 1.49
Prostaglandin E2 exacerbates collagen-induced arthritis in mice through the inflammatory interleukin-23/interleukin-17 axis. Arthritis Rheum (2007) 1.43
Overexpression of IL-17 in the knee joint of collagen type II immunized mice promotes collagen arthritis and aggravates joint destruction. Inflamm Res (2002) 1.41
Serum MMP-3 and MMP-1 and progression of joint damage in early rheumatoid arthritis. Rheumatology (Oxford) (2003) 1.32
Interleukin 17 induces cartilage collagen breakdown: novel synergistic effects in combination with proinflammatory cytokines. Ann Rheum Dis (2002) 1.31
Reduction of interleukin-17-induced inhibition of chondrocyte proteoglycan synthesis in intact murine articular cartilage by interleukin-4. Arthritis Rheum (2000) 1.29
Interleukin 17 synergises with tumour necrosis factor alpha to induce cartilage destruction in vitro. Ann Rheum Dis (2002) 1.24
Association of interleukin-18 expression with enhanced levels of both interleukin-1beta and tumor necrosis factor alpha in knee synovial tissue of patients with rheumatoid arthritis. Arthritis Rheum (2003) 1.17
Interleukin 17 (IL-17) induces collagenase-3 production in human osteoarthritic chondrocytes via AP-1 dependent activation: differential activation of AP-1 members by IL-17 and IL-1beta. J Rheumatol (2002) 1.15
Oncostatin M in combination with tumor necrosis factor alpha induces cartilage damage and matrix metalloproteinase expression in vitro and in vivo. Arthritis Rheum (2003) 1.15
Relationships of matrix metalloproteinases and their inhibitors to cartilage proteoglycan and collagen turnover and inflammation as revealed by analyses of synovial fluids from patients with rheumatoid arthritis. Arthritis Rheum (2001) 1.14
Effector function of type II collagen-stimulated T cells from rheumatoid arthritis patients: cross-talk between T cells and synovial fibroblasts. Arthritis Rheum (2004) 1.12
IL-17A versus IL-17F induced intracellular signal transduction pathways and modulation by IL-17RA and IL-17RC RNA interference in AGS gastric adenocarcinoma cells. Cytokine (2007) 1.07
T cell dependence of chronic destructive murine arthritis induced by repeated local activation of Toll-like receptor-driven pathways: crucial role of both interleukin-1beta and interleukin-17. Arthritis Rheum (2008) 1.06
The clinical role of IL-23p19 in patients with rheumatoid arthritis. Scand J Rheumatol (2007) 1.06
Amplifying elements of arthritis and joint destruction. Ann Rheum Dis (2007) 1.05
Radiographic joint damage in rheumatoid arthritis is associated with differences in cartilage turnover and can be predicted by serum biomarkers: an evaluation from 1 to 4 years after diagnosis. Arthritis Res Ther (2006) 1.04
Oncostatin M induces angiogenesis and cartilage degradation in rheumatoid arthritis synovial tissue and human cartilage cocultures. Arthritis Rheum (2006) 1.04
Angiogenesis and chemokines in rheumatoid arthritis and other systemic inflammatory rheumatic diseases. J Cell Mol Med (2002) 1.01
Associations between HLA-DRB1, RANK, RANKL, OPG, and IL-17 genotypes and disease severity phenotypes in Japanese patients with early rheumatoid arthritis. Clin Rheumatol (2007) 0.97
Serum and synovial fluid levels of p40 IL12/23 in spondyloarthropathy patients. Clin Rheumatol (2008) 0.96
Interleukin-17 gene expression in patients with rheumatoid arthritis. Mod Rheumatol (2007) 0.94
Early changes in serum type II collagen biomarkers predict radiographic progression at one year in inflammatory arthritis patients after biologic therapy. Arthritis Rheum (2007) 0.93
The role of arthroscopy in early arthritis. Clin Exp Rheumatol (1999) 0.93
Association of matrix metalloproteinase 3 promoter genotype with disease outcome in rheumatoid arthritis. Genes Immun (2004) 0.92
Can serum biomarker assays measure the progression of cartilage degeneration in osteoarthritis? Arthritis Rheum (2002) 0.89
Connective tissue metabolism in patients with unclassified polyarthritis and early rheumatoid arthritis. Relationship to disease activity, bone mineral density, and radiographic outcome. J Rheumatol (2004) 0.87
Molecular therapeutic targets in rheumatoid arthritis. Expert Rev Mol Med (2005) 0.85
[Correlations between serum matrix metalloproteinase (MMP-1, MMP-3, MMP-9, MMP-13) concentrations and markers of disease activity in early rheumatoid arthritis]. Przegl Lek (2005) 0.81
Treatment with anti-TNF-alpha antibody infliximab reduces serum IL-15 levels in patients with rheumatoid arthritis. Clin Rheumatol (2006) 0.81
Strangers at the benchside: research ethics consultation. Am J Bioeth (2008) 12.17
A genome-wide association study identifies new psoriasis susceptibility loci and an interaction between HLA-C and ERAP1. Nat Genet (2010) 8.48
2013 classification criteria for systemic sclerosis: an American College of Rheumatology/European League against Rheumatism collaborative initiative. Arthritis Rheum (2013) 5.99
Canadian Network for Mood and Anxiety Treatments (CANMAT) guidelines for the management of patients with bipolar disorder: consensus and controversies. Bipolar Disord (2005) 4.94
A multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma. Arthritis Rheum (2006) 3.45
2013 classification criteria for systemic sclerosis: an American college of rheumatology/European league against rheumatism collaborative initiative. Ann Rheum Dis (2013) 3.11
Common variants at TRAF3IP2 are associated with susceptibility to psoriatic arthritis and psoriasis. Nat Genet (2010) 2.56
Pyridoxine responsiveness in novel mutations of the PNPO gene. Neurology (2014) 2.38
The spectrum of SCN1A-related infantile epileptic encephalopathies. Brain (2007) 2.30
Acute-phase serum amyloid A regulates tumor necrosis factor α and matrix turnover and predicts disease progression in patients with inflammatory arthritis before and after biologic therapy. Arthritis Rheum (2011) 2.25
An international gap in human ES cell research. Nat Biotechnol (2006) 2.17
Systematic microanatomical analysis of CXCL13 and CCL21 in situ production and progressive lymphoid organization in rheumatoid synovitis. Eur J Immunol (2005) 1.96
Comparative assessment of leflunomide and methotrexate for the treatment of rheumatoid arthritis, by dynamic enhanced magnetic resonance imaging. Arthritis Rheum (2002) 1.92
Women, men, and rheumatoid arthritis: analyses of disease activity, disease characteristics, and treatments in the QUEST-RA study. Arthritis Res Ther (2009) 1.87
Patient perspective: fatigue as a recommended patient centered outcome measure in rheumatoid arthritis. J Rheumatol (2007) 1.87
Determination of the minimal clinically important difference in rheumatoid arthritis joint damage of the Sharp/van der Heijde and Larsen/Scott scoring methods by clinical experts and comparison with the smallest detectable difference. Arthritis Rheum (2002) 1.86
QUEST-RA: quantitative clinical assessment of patients with rheumatoid arthritis seen in standard rheumatology care in 15 countries. Ann Rheum Dis (2007) 1.83
Treating spondyloarthritis, including ankylosing spondylitis and psoriatic arthritis, to target: recommendations of an international task force. Ann Rheum Dis (2013) 1.74
Comparison of synovial tissues from the knee joints and the small joints of rheumatoid arthritis patients: Implications for pathogenesis and evaluation of treatment. Arthritis Rheum (2002) 1.67
Detecting radiological changes in rheumatoid arthritis that are considered important by clinical experts: influence of reading with or without known sequence. J Rheumatol (2002) 1.63
Identification of synovial biomarkers of response to experimental treatment in early-phase clinical trials in spondylarthritis. Arthritis Rheum (2006) 1.62
Pyridoxine dependent epilepsy and antiquitin deficiency: clinical and molecular characteristics and recommendations for diagnosis, treatment and follow-up. Mol Genet Metab (2011) 1.61
Consensus on a core set of domains for psoriatic arthritis. J Rheumatol (2007) 1.60
Research ethics consultation: the Stanford experience. IRB (2009) 1.58
Tumor necrosis factor blocking therapy alters joint inflammation and hypoxia. Arthritis Rheum (2011) 1.50
A randomized controlled trial with an anti-CCL2 (anti-monocyte chemotactic protein 1) monoclonal antibody in patients with rheumatoid arthritis. Arthritis Rheum (2006) 1.50
90Y-edotreotide for metastatic carcinoid refractory to octreotide. J Clin Oncol (2010) 1.49
HPV detection rate in discordant Pap tests between cytotechnologists and pathologists. Diagn Cytopathol (2009) 1.39
Angiopoietins, growth factors, and vascular morphology in early arthritis. J Rheumatol (2003) 1.38
Definitions and validation criteria for biomarkers and surrogate endpoints: development and testing of a quantitative hierarchical levels of evidence schema. J Rheumatol (2007) 1.35
Evaluating antirheumatic treatments using synovial biopsy: a recommendation for standardisation to be used in clinical trials. Ann Rheum Dis (2010) 1.28
Local expression of the serum amyloid A and formyl peptide receptor-like 1 genes in synovial tissue is associated with matrix metalloproteinase production in patients with inflammatory arthritis. Arthritis Rheum (2004) 1.25
Cytokine gene polymorphisms: association with psoriatic arthritis susceptibility and severity. Arthritis Rheum (2003) 1.22
The stem cell research environment: a patchwork of patchworks. Stem Cell Rev (2009) 1.21
Turnover of type II collagen and aggrecan in cartilage matrix at the onset of inflammatory arthritis in humans: relationship to mediators of systemic and local inflammation. Arthritis Rheum (2003) 1.18
Cardiovascular disease and risk factors in patients with psoriasis and psoriatic arthritis. J Rheumatol (2010) 1.17
Acute-phase serum amyloid A stimulation of angiogenesis, leukocyte recruitment, and matrix degradation in rheumatoid arthritis through an NF-kappaB-dependent signal transduction pathway. Arthritis Rheum (2006) 1.15
Angiogenesis and blood vessel stability in inflammatory arthritis. Arthritis Rheum (2010) 1.13
Activation of nuclear orphan receptor NURR1 transcription by NF-kappa B and cyclic adenosine 5'-monophosphate response element-binding protein in rheumatoid arthritis synovial tissue. J Immunol (2002) 1.13
Macrophages in synovial inflammation. Front Immunol (2011) 1.13
Reduction of synovial sublining layer inflammation and proinflammatory cytokine expression in psoriatic arthritis treated with methotrexate. Arthritis Rheum (2004) 1.12
Targeting interleukin-1 in the treatment of rheumatoid arthritis. Arthritis Rheum (2002) 1.12
International spondyloarthritis interobserver reliability exercise--the INSPIRE study: II. Assessment of peripheral joints, enthesitis, and dactylitis. J Rheumatol (2007) 1.11
Acute serum amyloid A induces migration, angiogenesis, and inflammation in synovial cells in vitro and in a human rheumatoid arthritis/SCID mouse chimera model. J Immunol (2010) 1.10
IL-17A expression is localised to both mononuclear and polymorphonuclear synovial cell infiltrates. PLoS One (2011) 1.10
Increased synovial tissue NF-kappa B1 expression at sites adjacent to the cartilage-pannus junction in rheumatoid arthritis. Arthritis Rheum (2004) 1.09
A direct test of potential roles for beta3 and beta5 integrins in growth and metastasis of murine mammary carcinomas. Cancer Res (2005) 1.08
Synovial tissue sublining CD68 expression is a biomarker of therapeutic response in rheumatoid arthritis clinical trials: consistency across centers. J Rheumatol (2009) 1.08
Assessing quality of sleep in patients with rheumatoid arthritis. J Rheumatol (2009) 1.06
Remission in psoriatic arthritis: is it possible and how can it be predicted? Arthritis Res Ther (2010) 1.06
Increased perivascular synovial membrane expression of myeloid-related proteins in psoriatic arthritis. Arthritis Rheum (2003) 1.05
Outcome measures in psoriatic arthritis. J Rheumatol (2007) 1.05
International spondyloarthritis interobserver reliability exercise--the INSPIRE study: I. Assessment of spinal measures. J Rheumatol (2007) 1.04
Interleukin-7 deficiency in rheumatoid arthritis: consequences for therapy-induced lymphopenia. Arthritis Res Ther (2004) 1.04
Oncostatin M induces angiogenesis and cartilage degradation in rheumatoid arthritis synovial tissue and human cartilage cocultures. Arthritis Rheum (2006) 1.04
Synovial tissue analysis for the discovery of diagnostic and prognostic biomarkers in patients with early arthritis. J Rheumatol (2011) 1.03
Blockade of Toll-like receptor 2 prevents spontaneous cytokine release from rheumatoid arthritis ex vivo synovial explant cultures. Arthritis Res Ther (2011) 1.03
Synovial macrophages as a biomarker of response to therapeutic intervention in rheumatoid arthritis: standardization and consistency across centers. J Rheumatol (2007) 1.02
Identification of Naf1/ABIN-1 among TNF-alpha-induced expressed genes in human synoviocytes using oligonucleotide microarrays. FEBS Lett (2003) 1.02
Modulation of orphan nuclear receptor NURR1 expression by methotrexate in human inflammatory joint disease involves adenosine A2A receptor-mediated responses. J Immunol (2005) 1.01
CCR5 blockade in rheumatoid arthritis: a randomised, double-blind, placebo-controlled clinical trial. Ann Rheum Dis (2010) 1.01
Reappraisal of OMERACT 8 draft validation criteria for a soluble biomarker reflecting structural damage endpoints in rheumatoid arthritis, psoriatic arthritis, and spondyloarthritis: the OMERACT 9 v2 criteria. J Rheumatol (2009) 1.00
Infections and biological therapy in rheumatoid arthritis. Best Pract Res Clin Rheumatol (2003) 1.00
Fatigue is a reliable, sensitive and unique outcome measure in rheumatoid arthritis. Rheumatology (Oxford) (2009) 0.98
Resolution of endothelial activation and down-regulation of Tie2 receptor in psoriatic skin after infliximab therapy. J Am Acad Dermatol (2006) 0.95